Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failure
Phase 3
- Conditions
- Heart failre with reduced EF(ejection fraction).Heart failure
- Registration Number
- IRCT20210809052117N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Age: 18 yr_80 yr
Heart failure with reduced EF <40%
Nondiabetic
Stable symptom and therapy for heart failure
Exclusion Criteria
Cardiovascular event, admission for cardiovascular or renal complications within last 3 months
Cancer or life-threatening condition
Estimated GFR < 45 ml/min/m2
Systolic blood pressure < 90mmhg
Pregnancy or lactating women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Echocardiography index. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Echocardiography.;Quality of life. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Kansas questionnaire.;Physical activity. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: NYHA Class and 6-MWT.
- Secondary Outcome Measures
Name Time Method Renal function. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Creatinine measuring and computing Glomerular Filtration Rate.;Cardiac mortality. Timepoint: During the study. Method of measurement: Follow up.;Myocardial Infurction. Timepoint: During the study. Method of measurement: Follow up.;Duration of hospitalization for cardiac causes. Timepoint: During the study. Method of measurement: Follow up.